Dublin, May 13, 2025 (GLOBE NEWSWIRE) — The “Saudi Arabia Pharmaceutical CDMO Market, By Region, Competition, Forecast & Opportunities, 2020-2030F” has been added to ResearchAndMarkets.com’s offering.
The Saudi Arabia Pharmaceutical CDMO Market, valued at USD 1.62 billion in 2024, is projected to reach USD 2.24 billion by 2030, expanding at a CAGR of 5.45%.
The market is fueled by increased domestic demand for pharmaceuticals, driven by demographic changes, healthcare needs, and evolving patient expectations. Saudi Arabia’s pharmaceutical sector is one of the largest in the region, with substantial investments being made to modernize infrastructure, improve healthcare services, and expand local manufacturing capabilities.
Key Market Drivers
Increasing domestic demand for pharmaceuticals is a significant growth driver, propelled by a growing and urbanizing population. The transition towards an older demographic and the rising prevalence of lifestyle-related diseases such as diabetes and hypertension further boost the demand. The government’s Vision 2030 initiative supports local manufacturing, reducing import dependence and fostering CDMO partnerships to enhance drug availability and affordability.
Health System Modernization
Health system modernization plays a pivotal role in market expansion. Reforms and policy shifts are enhancing healthcare delivery and access, leading to growing pharmaceutical needs. The rollout of universal health coverage will further accelerate drug demand. CDMOs are vital in meeting these demands by providing scalable, high-quality manufacturing solutions. Advanced medical technologies and specialized treatment centers are enhancing the sector’s sophistication and are supported by CDMOs in the production of biologics and personalized medicines.
Cost Efficiency and Global Competitiveness
Saudi Arabia’s strategic focus on local production enhances cost efficiency. Establishing manufacturing facilities within the kingdom reduces import costs and improves supply chain efficiency. The government’s financial incentives for local production further reduce operational costs, making Saudi-based CDMOs attractive partners globally. Technological advancements like automation and AI are optimizing production processes, enhancing competitiveness and enabling compliance with international regulatory standards.
Key Market Challenges
Regulatory and compliance barriers continue to pose challenges, although the Saudi Food and Drug Authority (SFDA) is making strides towards more streamlined processes. A shortage of skilled labor also affects manufacturing capabilities, despite ongoing investment in education and training. These factors add complexity to operations and impact scalability and international competitiveness.
Market Trends
Advanced manufacturing technologies are transforming the sector, with automation and AI playing crucial roles in enhancing efficiency and reducing costs. The shift towards biopharmaceuticals and specialty drugs presents new opportunities for CDMOs, fostering investment in specialized facilities. As the demand for these complex drugs rises, Saudi-based CDMOs are positioned to lead in biopharmaceutical manufacturing.
Segmental Insights
The Active Pharmaceutical Ingredient (API) segment dominates the Saudi CDMO market, driven by the demand for generic drugs. Investments in local API production reduce import reliance and enhance affordability. Regional insights show the Northern and Central regions as market leaders due to strategic geographic positions and developed infrastructure supporting efficient drug distribution.
Key Market Players
- Tabuk Manufacturing Company
- Lifera
- Saudi Bio, Kingdom of Saudi Arabia
- Fresenius Kabi MENA
- Hikma Pharmaceuticals PLC
- Pfizer Scientific Technical Limited Company
- Novartis AG
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 85 |
| Forecast Period | 2024 – 2030 |
| Estimated Market Value (USD) in 2024 | $1.62 Billion |
| Forecasted Market Value (USD) by 2030 | $2.24 Billion |
| Compound Annual Growth Rate | 5.4% |
| Regions Covered | Saudi Arabia |
Key Topics Covered:
1. Service Overview
1.1. Market Definition
1.2. Scope of the Market
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
3. Executive Summary
3.1. Overview of the Market
4. Voice of Customer
5. Saudi Arabia Pharmaceutical CDMO Market Outlook
5.1. Market Size & Forecast
5.2. Market Share & Forecast
6. Eastern Saudi Arabia Pharmaceutical CDMO Market Outlook
6.1. Market Size & Forecast
6.2. Market Share & Forecast
7. Western Saudi Arabia Pharmaceutical CDMO Market Outlook
7.1. Market Size & Forecast
7.2. Market Share & Forecast
8. Northern & Central Saudi Arabia Pharmaceutical CDMO Market Outlook
8.1. Market Size & Forecast
8.2. Market Share & Forecast
9. Southern Saudi Arabia Pharmaceutical CDMO Market Outlook
9.1. Market Size & Forecast
9.2. Market Share & Forecast
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
11.1. Recent Developments
12. Saudi Arabia Economic Profile
13. Saudi Arabia Pharmaceutical CDMO Market: SWOT Analysis
14. Competitive Landscape
- Tabuk Manufacturing Company
- Lifera
- Saudi Bio, Kingdom of Saudi Arabia
- Fresenius Kabi MENA
- Hikma Pharmaceuticals PLC
- Pfizer Scientific Technical Limited Company
- Novartis AG
For more information about this report visit https://www.researchandmarkets.com/r/lu9spu
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Saudi Arabian Pharmaceutical CDMO Market
